Literature DB >> 25993189

Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Helen J Mackay1, Lari Wenzel1, Linda Mileshkin1.   

Abstract

Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally it remains a leading cause of cancer-related death in women. Outcomes for patients who are diagnosed with anything but early-stage disease remain poor. Here we examine emerging strategies to improve the treatment of locally advanced disease. We discuss emerging biologic data, which are informing our investigation of new therapeutic interventions in persistent, recurrent, and metastatic cervical cancer. We recognize the importance of interventions to improve quality of life and to prevent long-term sequelae in women undergoing treatment. Finally, and perhaps most importantly, we recognize the need for global collaboration and advocacy to improve the outcome for all women at risk of and diagnosed with this disease.

Entities:  

Mesh:

Year:  2015        PMID: 25993189      PMCID: PMC4920478          DOI: 10.14694/EdBook_AM.2015.35.e299

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  126 in total

Review 1.  Host immune responses to cervical cancer.

Authors:  Swati Patel; Shubhada Chiplunkar
Journal:  Curr Opin Obstet Gynecol       Date:  2009-02       Impact factor: 1.927

2.  Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.

Authors:  Sang-Young Ryu; Won-Moo Lee; Kidong Kim; Sang-Il Park; Beob-Jong Kim; Moon-Hong Kim; Seok-Cheol Choi; Chul-Koo Cho; Byung-Ho Nam; Eui-Don Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-11       Impact factor: 7.038

3.  RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Authors:  Tracey Schefter; Kathryn Winter; Janice S Kwon; Kelly Stuhr; Khalid Balaraj; Brian Patrick Yaremko; William Small; William Sause; David Gaffney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

4.  Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?

Authors:  Andrew J Bishop; Pamela K Allen; Ann H Klopp; Larissa A Meyer; Patricia J Eifel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-25       Impact factor: 7.038

5.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

6.  Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Authors:  J E Kurtz; A-C Hardy-Bessard; M Deslandres; S Lavau-Denes; R Largillier; C Roemer-Becuwe; B Weber; C Guillemet; D Paraiso; E Pujade-Lauraine
Journal:  Gynecol Oncol       Date:  2009-02-15       Impact factor: 5.482

7.  Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Authors:  Sebastian Tuve; Bing-Mae Chen; Ying Liu; Tian-Lu Cheng; Papa Touré; Papa Salif Sow; Qinghua Feng; Nancy Kiviat; Robert Strauss; Shaoheng Ni; Zong-Yi Li; Steve R Roffler; André Lieber
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

8.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.

Authors:  Gopeshwar Narayan; Hugo Arias-Pulido; Subhadra V Nandula; Katia Basso; Dorcas D Sugirtharaj; Hernan Vargas; Mahesh Mansukhani; Jeannine Villella; Larissa Meyer; Achim Schneider; Lutz Gissmann; Matthias Dürst; Bhavana Pothuri; Vundavalli V V S Murty
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

9.  PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.

Authors:  John B McIntyre; Jackson S Wu; Peter S Craighead; Tien Phan; Martin Köbel; Susan P Lees-Miller; Prafull Ghatage; Anthony M Magliocco; Corinne M Doll
Journal:  Gynecol Oncol       Date:  2012-12-22       Impact factor: 5.482

10.  [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix].

Authors:  G Goudy; E Stoeckle; L Thomas; M Kind; F Guyon; V Brouste; A Floquet
Journal:  Bull Cancer       Date:  2009-06       Impact factor: 1.276

View more
  10 in total

1.  WASH regulates the oxidative stress Nrf2/ARE pathway to inhibit proliferation and promote apoptosis of HeLa cells under the action of Jolkinolide B.

Authors:  Yu Hong; Jicheng Liu; Wanying Kong; Hui Li; Ying Cui; Yuchao Liu; Zhihui Deng; Dezhi Ma; Keyong Zhang; Jinghui Li; Minhui Li
Journal:  PeerJ       Date:  2022-07-13       Impact factor: 3.061

Review 2.  [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer.

Authors:  Chitra Viswanathan; Silvana Faria; Catherine Devine; Madhavi Patnana; Tara Sagebiel; Revathy B Iyer; Priya R Bhosale
Journal:  PET Clin       Date:  2018-02-03

Review 3.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

4.  Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation.

Authors:  Yada Kanjanapan; Siddhartha Deb; Richard J Young; Mathias Bressel; Linda Mileshkin; Danny Rischin; Michael S Hofman; Kailash Narayan; Shankar Siva
Journal:  Clin Transl Radiat Oncol       Date:  2017-02-08

5.  Texture Analysis as Imaging Biomarker for recurrence in advanced cervical cancer treated with CCRT.

Authors:  Jie Meng; Shunli Liu; Lijing Zhu; Li Zhu; Huanhuan Wang; Li Xie; Yue Guan; Jian He; Xiaofeng Yang; Zhengyang Zhou
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

6.  MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study.

Authors:  Sharon L Giles; Georgios Imseeh; Ian Rivens; Gail R Ter Haar; Alexandra Taylor; Nandita M deSouza
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

7.  Combining Intravoxel Incoherent Motion Diffusion Weighted Imaging and Texture Analysis for a Nomogram to Predict Early Treatment Response to Concurrent Chemoradiotherapy in Cervical Cancer Patients.

Authors:  Xiaomin Zheng; Cuiping Li; Lufeng Zhang; Feng Cao; Xin Fang; Liting Qian; Jiangning Dong
Journal:  J Oncol       Date:  2021-12-24       Impact factor: 4.375

8.  The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis.

Authors:  Ruiling Yan; Hanlin Shuai; Xin Luo; Xueqin Wang; Baozhang Guan
Journal:  Biosci Rep       Date:  2017-10-06       Impact factor: 3.840

9.  SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients.

Authors:  Li-Ping Yang; Hai-Qin Feng; Jian-Cai Ma; Hong Wu; Cai-Ru Liu; Jun-de Hou
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

Review 10.  Radiomics in cervical and endometrial cancer.

Authors:  Lucia Manganaro; Gabriele Maria Nicolino; Miriam Dolciami; Federica Martorana; Anastasios Stathis; Ilaria Colombo; Stefania Rizzo
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.